Peanut Allergy Study
Research Question:
Does ligelizumab (QGE031), an injectable, improve allergic reactions to peanuts?
Basic Study Information
Purpose:
This study is designed to determine if there is a way to decrease sensitivity to peanuts
in patients with a peanut allergy.
There are 3 phases in this study: 1) Screening – 3 visits over to 4 weeks, 2) Treatment
– 52-weeks - 17 visits with injections once a month, 3) Follow-up – 4 visits over
4 months. The study will involve skin prick tests/food challenges. You will be reimbursed
for your participation. Eligibility: Ages 6-55, diagnosed with a peanut allergy,
willing to commit to a partnership with our study team and the researchers at Novartis
as we work to help patients with peanut allergy!
Study Reference #: Study00006879
Lead Researcher (Principal Investigator)
Lead Researcher:
Theresa Bingemann
Study Contact Information
Study Coordinator: Allison Leadley
Phone: (585) 275-4640
Email: allison_leadley@urmc.rochester.edu
Additional Study Details
Study Details:
This study is intensive. It lasts for about 17 months and has 24 study visits, including
skin prick tests and food challenges. We are looking for subjects dedicated to improving
the lives of people living with peanut allergy. Reimbursement is provided for each
study visit completed.
Number of Visits:
More than 10
Parking:
Reimbursed
Transportation Coverage:
No
Reimbursement:
Yes
Payment Details:
$1,800 stipend if ALL study visits completed. Partial payment received after each
visit.
Learn More About These Conditions
More information about Anaphylaxis
More information about Peanut Hypersensitivity
Trial Not Found
The study you are looking for is not active at this time.
Return to Search